CN Patent

CN114949200B — 全反式维a酸联合低剂量利妥昔单抗在制备治疗激素耐药或复发itp的药物中的应用

Assigned to Peking University Peoples Hospital · Expires 2025-08-19 · 1y expired

What this patent protects

本发明提供全反式维A酸联合低剂量利妥昔单抗在制备治疗激素耐药或复发ITP的药物中的应用。利妥昔单抗的用量为100mg每周；全反式维A酸的用量为20mg每平方米体表面积每天。多中心随机对照试验表明ATRA联合LD‑RTX对比LD‑RTX单药应用治疗激素耐药或复发ITP患者具有更好的疗效及安全性。

USPTO Abstract

本发明提供全反式维A酸联合低剂量利妥昔单抗在制备治疗激素耐药或复发ITP的药物中的应用。利妥昔单抗的用量为100mg每周；全反式维A酸的用量为20mg每平方米体表面积每天。多中心随机对照试验表明ATRA联合LD‑RTX对比LD‑RTX单药应用治疗激素耐药或复发ITP患者具有更好的疗效及安全性。

Drugs covered by this patent

Patent Metadata

Patent number
CN114949200B
Jurisdiction
CN
Classification
—
Expires
2025-08-19
Drug substance claim
No
Drug product claim
No
Assignee
Peking University Peoples Hospital
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.